Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) Non Operating Income (2021 - 2025)

Historic Non Operating Income for Agios Pharmaceuticals (AGIO) over the last 5 years, with Q3 2025 value amounting to $67000.0.

  • Agios Pharmaceuticals' Non Operating Income fell 9594.19% to $67000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 4730.12%. This contributed to the annual value of $6.5 million for FY2024, which is 713.46% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Non Operating Income stood at $67000.0 for Q3 2025, which was down 9594.19% from $523000.0 recorded in Q2 2025.
  • Agios Pharmaceuticals' Non Operating Income's 5-year high stood at $6.5 million during Q2 2021, with a 5-year trough of $67000.0 in Q3 2025.
  • For the 5-year period, Agios Pharmaceuticals' Non Operating Income averaged around $2.0 million, with its median value being $1.6 million (2024).
  • Its Non Operating Income has fluctuated over the past 5 years, first soared by 3781.3% in 2024, then tumbled by 9594.19% in 2025.
  • Agios Pharmaceuticals' Non Operating Income (Quarter) stood at $3.3 million in 2021, then crashed by 58.48% to $1.4 million in 2022, then rose by 26.23% to $1.7 million in 2023, then decreased by 5.25% to $1.6 million in 2024, then crashed by 95.87% to $67000.0 in 2025.
  • Its last three reported values are $67000.0 in Q3 2025, $523000.0 for Q2 2025, and $1.3 million during Q1 2025.